Interferon-alpha for chronic hepatitis C: reducing the uncertainties
Article Abstract:
Evidence is mounting that interferon-alpha may be both effective and affordable in the treatment of chronic hepatitis C. Three studies provide support for this optimistic outlook. A 1 to 7.6-year follow-up study on 80 patients who had a sustained response to therapy after 6 months found that the response was maintained in the majority of the patients. Another analysis indicates that 6 months of interferon-alpha therapy for mild chronic hepatitis C is beneficial and cost effective. The third supports the advantages and cost-effectiveness of 12 months of therapy compared to 6 months, and no treatment.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
Article Abstract:
The authors discuss the current day situation of hepatitis B viral infection, the leading cause of liver cancer and cirrhosis in the world. Hepatitis B infection is especially widespread in southeast Asia, China, and Africa, where it there are areas in which the infection rate is nearly 10% of the population. About 1.25 million people in North America and Europe are infected. treatment was once limited to interferon-alfa, but advances have been made in the field of nucleoside analogues such as lamivudine, which is effective to one degree or another in almost every patient.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Does interferon-alpha prevent recurrence of malignant tumors in patients with hepatitis C-related liver cancer?
Article Abstract:
Interferon-alpha may prevent the re-occurrence of liver cancer caused by hepatitis C in patients who had the initial tumor surgically removed. In a study of 30 patients, the cancer recurred in 5 of the 15 who took interferon-alpha and in 12 of the 15 who did not take interferon-alpha.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Interferon beta-1B for multiple sclerosis. Glatiramer acetate for relapsing multiple sclerosis. Interferon beta-1a for relapsing multiple sclerosis
- Abstracts: Caring for neonates. Taking the strain. Tuberculosis in homeless people
- Abstracts: Hard-arm vibration research. Finding the fatal fibre
- Abstracts: Prevalence of selected risk factors for chronic disease by education level in racial ethnic populations - United States, 1991-1992
- Abstracts: Visual impairment in a rural Appalachian community: prevalence and causes. Acute Onset of Decreased Vision and Hearing Traced to Hemodialysis Treatment With Aged Dialyzers